干扰素在严重急性呼吸综合征治疗中的作用。
Role of interferons in the treatment of severe acute respiratory syndrome.
作者信息
Cinatl Jindrich, Michaelis Martin, Scholz Martin, Doerr Hans Wilhelm
机构信息
Klinikum der Johann Wolfgang Goethe-Universitat, Institut für Medizinische Virologie, Paul Ehrlich-Str. 40, 60596 Frankfurt am Main, Germany.
出版信息
Expert Opin Biol Ther. 2004 Jun;4(6):827-36. doi: 10.1517/14712598.4.6.827.
Severe acute respiratory syndrome (SARS) is caused by the SARS coronavirus (SCV). The disease appeared in the Guandong province of southern China in 2002. The epidemic affected > 8422 patients and caused 908 deaths in 29 countries on 5 continents. Several treatment modalities were tried with limited success to treat SARS and a variety of experimental drugs are under development. Type I interferons (IFNs-alpha/beta) were suggested as potential candidates to treat SARS. Several animal and human coronaviruses, including SCV, were shown to be sensitive to IFNs both in vitro and in vivo. A pilot clinical report showed effectiveness of IFN-alpha for the treatment of SARS patients. This review summarises antiviral activities of IFNs with special regard to SARS, and reviews the published clinical and experimental data describing the use of IFNs for SARS.
严重急性呼吸综合征（SARS）由SARS冠状病毒（SCV）引起。该疾病于2002年出现在中国南方的广东省。这场疫情影响了五大洲29个国家的8422多名患者，并导致908人死亡。人们尝试了多种治疗方式来治疗SARS，但成效有限，目前有多种实验性药物正在研发中。I型干扰素（IFN-α/β）被认为是治疗SARS的潜在候选药物。包括SCV在内的几种动物和人类冠状病毒在体外和体内均显示对IFN敏感。一份初步临床报告显示IFN-α对治疗SARS患者有效。本综述总结了IFN的抗病毒活性，特别关注SARS，并回顾了已发表的描述IFN用于SARS治疗的临床和实验数据。
Zotero 插件